search
Back to results

Short Adherence Intervention for Viral Re-suppression (SAVIR)

Primary Purpose

Adherence, Medication, HIV/AIDS

Status
Completed
Phase
Not Applicable
Locations
Lesotho
Study Type
Interventional
Intervention
Structured adherence counseling
Sponsored by
Swiss Tropical & Public Health Institute
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional health services research trial for Adherence, Medication focused on measuring HIV, Adherence, Viral re-suppression, Step-wedgged randomized trial

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All patients receiving VL monitoring at one of the 2 hospitals and 10 health centres in Butha-Buthe district
  • Patients on first-line ART
  • Patients with a VL≥ 1000 copies/mL after a minimum of 6 months on first-line ART

Exclusion Criteria:

  • Patients receiving VL monitoring at a non-participating center in Butha-Buthe

Sites / Locations

  • Boiketsiso Health Center
  • Linakeng Health Center
  • Makhunoane Health Center
  • Motete Health Center
  • Muela Health Center
  • Ngoajane Health Center
  • Paballong
  • Rampai Health Center
  • Seboche
  • St Paul Health Center
  • St Peters Health Center
  • Tsime Health Center

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Enhanced adherence counseling

Structured EAC plus SMS

Arm Description

Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.

The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.

Outcomes

Primary Outcome Measures

Re-suppression rates after one elevated viral load
HIV viral load <1000 copies/ml

Secondary Outcome Measures

Rates of switch to second-line ART
Any switch to protease-inhibitor based ART
Major drug resistance mutations
Presence of any major drug resistance mutation in those with 2nd elevated VL
Rates of attrition from care
No attendance at the clinic within 6 months after informing the patient about his/her first elevated VL
Rates of viral re-suppression
In those who switched to 2nd line

Full Information

First Posted
August 2, 2017
Last Updated
December 16, 2019
Sponsor
Swiss Tropical & Public Health Institute
Collaborators
SolidarMed, Ministry of Health, Lesotho, University of Basel
search

1. Study Identification

Unique Protocol Identification Number
NCT03242980
Brief Title
Short Adherence Intervention for Viral Re-suppression
Acronym
SAVIR
Official Title
Short Adherence Intervention for Viral Re-suppression (SAVIR) Study: A Stepped Wedge Randomized Controlled Study to Assess the Effect of Standardized Adherence Counselling in Individuals With Unsuppressed Viral Load in Lesotho
Study Type
Interventional

2. Study Status

Record Verification Date
December 2019
Overall Recruitment Status
Completed
Study Start Date
May 18, 2017 (Actual)
Primary Completion Date
August 1, 2019 (Actual)
Study Completion Date
December 1, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Swiss Tropical & Public Health Institute
Collaborators
SolidarMed, Ministry of Health, Lesotho, University of Basel

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
In the era of test-and-treat, with anticipated high numbers of patients who will have unsuppressed viral load (VL) due to poor adherence, simple, short and standardized adherence interventions with documented efficacy will be needed. Achieving re-suppression in patients with unsuppressed VL is beneficial for the health of the individual, important to reduce the risk of transmission and has a direct cost implication because patients with sustained unsuppressed VL will ultimately be switched to more expensive 2nd-line regimens. Information is still largely lacking on how to best address adherence problems among patients with unsuppressed VL. VL monitoring is recognized as a useful tool to reinforce adherence in patients with unsuppressed VL. The Lesotho Guidelines recommend redoing a VL 8-12 weeks after the first enhanced adherence counselling. To date no study has been published clearly demonstrating higher re-suppression rates after enhanced adherence counselling for patients with unsuppressed VL. This project aims to test an adherence intervention for HIV-positive individuals on first-line ART who have an unsuppressed viral load. A step wedged study will be used to compare the effectiveness of a short, standardized adherence counselling followed by an SMS reminder to the standard of care (≥ 2 unstructured adherence counselling sessions) in terms of viral re-suppression rates and switches to 2nd line ART.
Detailed Description
Due to a lack of routine viral load (VL) monitoring in Lesotho until now, most health care workers in the districts lack the necessary information on how to manage patients with elevated viral loads. The CART-1 study found re-suppression rates of only 30% with only 70% returning for a second VL. From these estimates, it is clear that the current practice for managing these patients must be improved. A simple intervention has been designed that could be feasibly adapted at all health centres in Lesotho. To ensure that the effect of this intervention is measured and to avoid a long delay in adopting the intervention, a stepped wedge design was chosen. In addition the study would thus not disrupt the on-going staggered roll-out of routine viral load provision to patients on ART at the 12 health facilities. Stepped wedge designs are a form of clustered study in which the intervention is delivered to groups rather than individuals. In this case, the cluster is the hospital or health centre. Each health centre will undergo a time period with the standard of care and then will be randomly selected to cross-over to the intervention at different time points, until all of the health centres have crossed-over to receive the intervention. Data on the endpoint will be collected continuously at all health centres. The use of a step wedged study is pragmatic - the intervention is offered to exert its expected benefits and research insight is a secondary aim. This innovative design will lead to much stronger evidence than observational studies. Routine VL (viral load) monitoring started in Butha-Buthe hospital in December 2015, in Seboche Hospital in May 2016 and the remaining 10 health centres in June 2016. Once each hospital/health center has implemented routine VL monitoring for a least 12 weeks, the standardized adherence intervention will be rolled out to the hospitals/health centers in a randomized fashion. Every 12 weeks starting in May 2017, two hospitals/health centers will be randomly selected to start with the adherence intervention. Randomization times will be separated by 12 weeks to allow for implementation and assessment of the intervention within each time period. Final data collection will occur in October 2018. All nurses at the centres will be trained in the standardized adherence counselling by an experienced professional counselor and an experienced ART nurse prior to the introduction of the intervention. The tracing of patients who do not show up for adherence counselling sessions or confirmatory VL will be done according to the current system in use at the health centre (usually contact individual via village health worker or phone if available) and will remain the same during both the control and intervention period.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adherence, Medication, HIV/AIDS
Keywords
HIV, Adherence, Viral re-suppression, Step-wedgged randomized trial

7. Study Design

Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Sequential Assignment
Model Description
To ensure that the effect of this intervention is measured and to avoid a long delay in adopting the intervention, a stepped wedge design was chosen. In addition the study would thus not disrupt the on-going staggered roll-out of routine viral load provision to patients on ART at the 12 health facilities. Stepped wedge designs are a form of clustered study in which the intervention is delivered to groups rather than individuals.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
928 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Enhanced adherence counseling
Arm Type
No Intervention
Arm Description
Individuals with elevated VL are required to attend a minimum of 2 session of enhanced adherence counselling performed at monthly intervals. A follow-up VL is done at 8 to 12 weeks after the first counselling session.
Arm Title
Structured EAC plus SMS
Arm Type
Experimental
Arm Description
The behavioral intervention will consist of structured adherence counseling and a short text message (SMS). A culturally adapted graphical brochure was specifically developed to guide adherence-counselling for individuals with unsuppressed VL.
Intervention Type
Behavioral
Intervention Name(s)
Structured adherence counseling
Intervention Description
Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home. Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling.
Primary Outcome Measure Information:
Title
Re-suppression rates after one elevated viral load
Description
HIV viral load <1000 copies/ml
Time Frame
Up to 16 weeks
Secondary Outcome Measure Information:
Title
Rates of switch to second-line ART
Description
Any switch to protease-inhibitor based ART
Time Frame
Up to 6 months
Title
Major drug resistance mutations
Description
Presence of any major drug resistance mutation in those with 2nd elevated VL
Time Frame
3 months after 1st elevated VL
Title
Rates of attrition from care
Description
No attendance at the clinic within 6 months after informing the patient about his/her first elevated VL
Time Frame
6 months
Title
Rates of viral re-suppression
Description
In those who switched to 2nd line
Time Frame
6 months after switch

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All patients receiving VL monitoring at one of the 2 hospitals and 10 health centres in Butha-Buthe district Patients on first-line ART Patients with a VL≥ 1000 copies/mL after a minimum of 6 months on first-line ART Exclusion Criteria: Patients receiving VL monitoring at a non-participating center in Butha-Buthe
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Tracy R Glass, PhD
Organizational Affiliation
Swiss TPH
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Niklaus Labhardt, MD
Organizational Affiliation
Swiss TPH
Official's Role
Study Chair
Facility Information:
Facility Name
Boiketsiso Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Linakeng Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Makhunoane Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Motete Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Muela Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Ngoajane Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Paballong
City
Butha-Buthe
Country
Lesotho
Facility Name
Rampai Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Seboche
City
Butha-Buthe
Country
Lesotho
Facility Name
St Paul Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
St Peters Health Center
City
Butha-Buthe
Country
Lesotho
Facility Name
Tsime Health Center
City
Butha-Buthe
Country
Lesotho

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
Citation
Government of Lesotho: NATIONAL GUIDELINES ON THE USE OF ANTIRETROVIRAL THERAPY FOR HIV PREVENTION AND TREATMENT. Fifth Edition 2016.
Results Reference
background
PubMed Identifier
17525686
Citation
Conway B. The role of adherence to antiretroviral therapy in the management of HIV infection. J Acquir Immune Defic Syndr. 2007 Jun 1;45 Suppl 1:S14-8. doi: 10.1097/QAI.0b013e3180600766.
Results Reference
background
PubMed Identifier
23774877
Citation
Bonner K, Mezochow A, Roberts T, Ford N, Cohn J. Viral load monitoring as a tool to reinforce adherence: a systematic review. J Acquir Immune Defic Syndr. 2013 Sep 1;64(1):74-8. doi: 10.1097/QAI.0b013e31829f05ac.
Results Reference
background
PubMed Identifier
25695494
Citation
Jobanputra K, Parker LA, Azih C, Okello V, Maphalala G, Kershberger B, Khogali M, Lujan J, Antierens A, Teck R, Ellman T, Kosgei R, Reid T. Factors associated with virological failure and suppression after enhanced adherence counselling, in children, adolescents and adults on antiretroviral therapy for HIV in Swaziland. PLoS One. 2015 Feb 19;10(2):e0116144. doi: 10.1371/journal.pone.0116144. eCollection 2015.
Results Reference
background
Citation
Ministry of Health and Social Welfare Lesotho: National Guidelines For HIV Testing And Counselling. National Guidelines For HIV Testing And Counselling 2009.
Results Reference
background

Learn more about this trial

Short Adherence Intervention for Viral Re-suppression

We'll reach out to this number within 24 hrs